The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals. It has its own manufacturing facility at Goa. It sells products through independent ...

As Sanofi moves forward with talks to potentially sell a 50% stake its consumer health unit Opella, fears of job cuts and drug shortages have prompted a call for industrial action in the company ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of ...

Sanofi on Friday said it’s in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French ...

NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...

Subhash Velingkar, the former chief of the RSS in Goa, presented himself to the police for the second day in a row on Friday regarding allegations of hurting religious sentiments. The Bicholim police ...

Now it’s trading hands again, through a deal announced Friday. Sanofi is selling global rights to Enjaymo to the Italy-based drugmaker Recordati, in exchange for an upfront payment of $825 million.

NEW YORK, Sept 23 (Reuters) - Sanofi's (SASY.PA), opens new tab chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new ...